Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Lymphoma Channel

Explore the latest updates and expert interviews

The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Latest Videos Types Subtypes The Lymphoma Sessions Conferences Topics Features Podcasts Expert Editorial Board

Welcome to The Lymphoma Channel

VJHemOnc brings you the latest updates in lymphoma, directly from the experts. Alongside our world-leading Editorial Board, The Lymphoma Channel covers all of the latest updates in lymphoma presented at international congresses – including video interviews, podcasts and roundtable discussions.

Dive into The Lymphoma Channel to learn more about the latest advances in therapy, including CAR-T, antibody-drug conjugates, checkpoint inhibitors and targeted therapies. As well as updates in therapy, The Lymphoma Channel also covers the latest research in biomarkers, treating relapsed disease, optimal patient selection and more.

Conferences

EHA 2026
ASCO 2026
EBMT 2026
CAR-T Meeting 2026
Tandem Meetings 2026
ASH 2025
1:27
The current role of BTK inhibitors in follicular lymphoma
Alexey Danilov • 13 Jun 2026
1:28
Subgroup analysis of the EPCORE FL-1 trial: efficacy of epcoritamab plus R-squared in R/R FL
Benoit Tessoulin • 17 Jun 2026
1:02
Next-generation CAR-T strategies aim to improve outcomes in large B-Cell lymphoma
Nirav Niranjan Shah • 13 Jun 2026
2:21
Why have BTK inhibitors not had the same impact in FL as in other B-cell malignancies?
Alexey Danilov • 13 Jun 2026
View All Videos
0:56
Using BTK inhibitors in patients with underlying cardiac comorbidities
Yasmin Karimi • 1 Jun 2026
2:24
Improving the outcomes of patients with MCL who progress on BTK inhibitors
Manali Kamdar • 30 May 2026
0:59
Could BTKis play a role in DLBCL through rational combinations?
Manali Kamdar • 30 May 2026
1:23
Promising approaches for managing patients with MCL with prior BTKi exposure
Yasmin Karimi • 1 Jun 2026
View All Videos
3:43
Overcoming common misconceptions about CAR-T in DLBCL
Anna Sureda • 18 Mar 2026
2:41
A study assessing the impact of time in patients with LBCL who are candidates for CAR T-cell therapy
Leyre Bento De Miguel • 27 Mar 2026
1:15
Comparing the patient experience with CAR-T versus transplant in LBCL
Lorna Warwick • 24 Mar 2026
1:54
Insights into the current role of BTK inhibitors for treating Waldenström’s in the UK
Charalampia Kyriakou • 25 Mar 2026
View All Videos
1:18
The potential of dual-targeting CAR-T approaches in R/R LBCL
Gloria Iacoboni • 20 Feb 2026
1:43
The challenges and factors to consider when selecting between CAR-T products for DLBCL
Leyre Bento De Miguel • 16 Feb 2026
2:42
Comparing clinical trial data and real-world evidence to inform CAR T-cell therapy in DLBCL
Leyre Bento De Miguel • 16 Feb 2026
7:44
The selective targeting of T-cell malignancies using a TRBC1-directed CAR T-cell therapy
Anna De Lucia • 20 Feb 2026
View All Videos
1:32
Baseline factors that should be assessed before selecting a frontline regimen for MCL
Krish Patel • 19 Feb 2026
2:34
Optimizing the treatment of B-cell malignancies: progress and challenges
Nirav Niranjan Shah • 16 Feb 2026
1:54
Frontline treatment in mantle cell lymphoma: defining the optimal approach
Krish Patel • 19 Feb 2026
1:24
The changing role of transplant in MCL with the incorporation of BTK inhibitors into upfront therapy
Krish Patel • 19 Feb 2026
View All Videos
2:09
Real-world ibrutinib plus venetoclax in frontline CLL/SLL: REALITY-WW and REALITY-2 outcomes
Paolo Ghia • 5 Dec 2025
2:07
Follicular Lymphoma Foundation: research mission, biomarkers, and global collaboration
Mitch Smith • 6 Dec 2025
4:37
CXCL10-CXCR3 signaling as a pro-survival pathway and prognostic biomarker in CNS lymphoma
James Rubenstein • 7 Dec 2025
1:37
Patient-informed CRISPR screening reveals gene targets to improve CAR T-cell efficacy
Joseph Melenhorst • 5 Dec 2025
View All Videos

loretta-nastoupil
Loretta Nastoupil
MD
Southwest Oncology
tycel-phillips
Tycel Phillips
MD
City of Hope
frederick-locke
Frederick Locke
MD
Moffitt Cancer Center
jessica-okosun
Jessica Okosun
MA, MB BChir, MRCP, FRCPath, PhD
Barts Cancer Institute, Queen Mary University of London
jeremy-abramson
Jeremy Abramson
MD
Massachusetts General Hospital Cancer Center
gloria-iacoboni
Gloria Iacoboni
MD, PhD
Vall d’Hebron Institute of Oncology

The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).

Diamond Supporter

AstraZeneca

Gold Supporter

BMS Johnson & Johnson

Silver Supporter

Takeda

Bronze Supporter

Galapagos

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

If you are interested in becoming a supporter of The Lymphoma Channel, please contact us.

The content of VJHemOnc is intended for healthcare professionals